3-O-Formyl-20R,21-epoxyresibufogenin suppresses IL-6-type cytokine actions by targeting the glycoprotein 130 subunit: Potential clinical implications

Journal of Allergy and Clinical Immunology

Volumn 120, Issue 2, 2007, Pages 437-444

  Kino, Tomoshige ^a   Boos, Terrence L ^b   Sulima, Agnieszka ^b   Siegel, Elise M ^b   Gold, Philip W ^c   Rice, Kenner C ^b   Chrousos, George P ^a,d  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^d UNIVERSITY OF ATHENS   (Greece)

Author keywords

glycoprotein 130; hepatic acute phase proteins; IL 6 receptor; signal transducer and activator of transcription 3

Indexed keywords

3 O FORMYL 21 EPOXYRESIBUFOGENIN; ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 2 MACROGLOBULIN; C REACTIVE PROTEIN; CHINESE DRUG; FIBRINOGEN; FIBRINOGEN B BETA CHAIN; GLYCOPROTEIN; GLYCOPROTEIN 130; INTERLEUKIN 11; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; METHIONINE ADENOSYLTRANSFERASE; METHIONINE ADENOSYLTRANSFERASE 2A; ONCOSTATIN M; OROSOMUCOID; PROTEIN SUBUNIT; STAT3 PROTEIN; TB 2 081; TB 2 082; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STRAIN HEPG2; CHINESE MEDICINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SYNTHESIS; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN TARGETING; RAT;

ALPHA 1-ANTICHYMOTRYPSIN; ALPHA-MACROGLOBULINS; ANIMALS; BUFANOLIDES; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOGEN; GLYCOPROTEINS; HUMANS; INTERLEUKIN-11; INTERLEUKIN-6; ONCOSTATIN M; OROSOMUCOID; PHOSPHORYLATION; RATS; RECEPTORS, INTERLEUKIN-6; RNA, MESSENGER; SOLUBILITY; STAT3 TRANSCRIPTION FACTOR;

EID: 34547107078     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2007.03.018     Document Type: Article

References (35)

1. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., and Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374 (2003) 1-20
2. Elenkov I.J., Iezzoni D.G., Daly A., Harris A.G., and Chrousos G.P. Cytokine dysregulation, inflammation and well-being. Neuroimmunomodulation 12 (2005) 255-269
3. Ishihara K., and Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 13 (2002) 357-368
4. Nishimoto N. Interleukin-6 in rheumatoid arthritis. Curr Opin Rheumatol 18 (2006) 277-281
5. Manolagas S.C. The role of IL-6 type cytokines and their receptors in bone. Ann N Y Acad Sci 840 (1998) 194-204
6. Alesci S., Martinez P.E., Kelkar S., Ilias I., Ronsaville D.S., Listwak S.J., et al. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J Clin Endocrinol Metab 90 (2005) 2522-2530
7. Spronk H.M., van der Voort D., and Ten Cate H. Blood coagulation and the risk of atherothrombosis: a complex relationship. Thromb J 2 (2004) 12-21
8. Ramadori G., and Christ B. Cytokines and the hepatic acute-phase response. Semin Liver Dis 19 (1999) 141-155
9. Taga T., and Kishimoto T. gp130 And the interleukin-6 family of cytokines. Annu Rev Immunol 15 (1997) 797-819
10. Kishimoto T. Interleukin-6: from basic science to medicine: 40 years in immunology. Annu Rev Immunol 23 (2005) 1-21
11. Heim M.H. The Jak-STAT pathway: specific signal transduction from the cell membrane to the nucleus. Eur J Clin Invest 26 (1996) 1-12
12. Hayashi M., Rho M.C., Fukami A., Enomoto A., Nonaka S., Sekiguchi Y., et al. Biological activity of a novel nonpeptide antagonist to the interleukin-6 receptor 20S,21-epoxy-resibufogenin-3-formate. J Pharmacol Exp Ther 303 (2002) 104-109
13. Enomoto A., Rho M.C., Komiyama K., and Hayashi M. Inhibitory effects of bufadienolides on interleukin-6 in MH-60 cells. J Nat Prod 67 (2004) 2070-2072
14. Kamano Y., Nogawa T., Yamashita A., Hayashi M., Inoue M., Drasar P., et al. Isolation and structure of a 20,21-epoxybufenolide series from "Ch'an Su.". J Nat Prod 65 (2002) 1001-1005
15. Kino T., Tiulpakov A., Ichijo T., Chheng L., Kozasa T., and Chrousos G.P. G protein β interacts with the glucocorticoid receptor and suppresses its transcriptional activity in the nucleus. J Cell Biol 169 (2005) 885-896
16. Ichijo T., Voutetakis A., Cotrim A.P., Bhattachryya N., Fujii M., Chrousos G.P., et al. The Smad6-histone deacetylase 3 complex silences the transcriptional activity of the glucocorticoid receptor: potential clinical implications. J Biol Chem 280 (2005) 42067-42077
17. Kino T., Rice K.C., and Chrousos G.P. The PPARδ agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition. Eur J Clin Invest 37 (2007) 425-433
18. Akabane H., Miyagawa N., Nii H., Inami Y., Togawa M., Tanaka H., et al. The effect of a newly synthesized indazole compound, TAS-3-124, on experimental autoimmune disease. Biol Pharm Bull 27 (2004) 1218-1223
19. Yang H., Sadda M.R., Yu V., Zeng Y., Lee T.D., Ou X., et al. Induction of human methionine adenosyltransferase 2A expression by tumor necrosis factor α: role of NF-κB and AP-1. J Biol Chem 278 (2003) 50887-50896
20. Baumann H., and Gauldie J. The acute phase response. Immunol Today 15 (1994) 74-80
21. Baumann H., Isseroff H., Latimer J.J., and Jahreis G.P. Phorbol ester modulates interleukin 6- and interleukin 1-regulated expression of acute phase plasma proteins in hepatoma cells. J Biol Chem 263 (1988) 17390-17396
22. Saito T., Yasukawa K., Suzuki H., Futatsugi K., Fukunaga T., Yokomizo C., et al. Preparation of soluble murine IL-6 receptor and anti-murine IL-6 receptor antibodies. J Immunol 147 (1991) 168-173
23. Narazaki M., Yasukawa K., Saito T., Ohsugi Y., Fukui H., Koishihara Y., et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82 (1993) 1120-1126
24. Nishimoto N., and Kishimoto T. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol 4 (2004) 386-391
25. Gadient R.A., and Patterson P.H. Leukemia inhibitory factor, Interleukin 6, and other cytokines using the GP130 transducing receptor: roles in inflammation and injury. Stem Cells 17 (1999) 127-137
26. Horton A.R., Davies A.M., Buj-Bello A., Bartlett P., and Murphy M. Leukemia inhibitory factor and ciliary neurotrophic factor in sensory neuron development. Perspect Dev Neurobiol 4 (1996) 35-38
27. Latchman D.S. Cardiotrophin-1: a novel cytokine and its effects in the heart and other tissues. Pharmacol Ther 85 (2000) 29-37
28. Kimber S.J. Leukaemia inhibitory factor in implantation and uterine biology. Reproduction 130 (2005) 131-145
29. Haraoui B. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis. J Rheumatol Suppl 72 (2005) 46-47
30. McClung M.R. Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies. Curr Osteoporos Rep 4 (2006) 28-33
31. Yang Z., Feng J., Li Y., Hu M., Song L., Yu M., et al. Structure-based design and characterization of a Novel IL-6 antagonist peptide. Mol Immunol 42 (2005) 1015-1021
32. Mihara M., Nishimoto N., and Ohsugi Y. The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther 5 (2005) 683-690
33. Enomoto A., Rho M.C., Fukami A., Hiraku O., Komiyama K., and Hayashi M. Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist. Biochem Biophys Res Commun 323 (2004) 1096-1102
34. Sobota R., Szwed M., Kasza A., Bugno M., and Kordula T. Parthenolide inhibits activation of signal transducers and activators of transcription (STATs) induced by cytokines of the IL-6 family. Biochem Biophys Res Commun 267 (2000) 329-333
35. Hayashi M., Rho M.C., Enomoto A., Fukami A., Kim Y.P., Kikuchi Y., et al. Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130. Proc Natl Acad Sci U S A 99 (2002) 14728-14733